Rivastigmine effects on EEG spectra and three-dimensional LORETA functional imaging in Alzheimer’s disease

Author： Gianotti Lorena   Künig Gabriella   Faber Pascal   Lehmann Dietrich   Pascual-Marqui Roberto   Kochi Kieko   Schreiter-Gasser Ursula  

Publisher： Springer Publishing Company

ISSN： 0033-3158

Source： Psychopharmacology, Vol.198, Iss.3, 2008-06, pp. : 323-332

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Review of rivastigmine and its clinical applications in Alzheimer’s disease and related disorders

By Desai A.   Grossberg G.  

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 4, 2001-04 ,pp. : 653-666

Informa Healthcare

Access to resources Recommend Favorite

Rivastigmine: A Pharmacoeconomic Review of its Use in Alzheimer’s Disease

By Lamb H.M.   Goa K.L.  

PharmacoEconomics, Vol. 19, Iss. 3, 2001-03 ,pp. : 303-318

Adis International

Access to resources Recommend Favorite

Risk of Antipsychotic Drug Use in Patients with Alzheimer’s Disease Treated with Rivastigmine

By Suh D-C.  

Drugs & Aging, Vol. 21, Iss. 6, 2004-01 ,pp. : 395-403

Adis International

Access to resources Recommend Favorite

Long-Term Effects of Rivastigmine Treatment on the Need for Psychotropic Medications in Nursing Home Patients with Alzheimer’s Disease: Results of a 52-Week Open-Label Study

By Edwards Keith  

Clinical Drug Investigation, Vol. 25, Iss. 8, 2005-01 ,pp. : 507-515

Adis International

Access to resources Recommend Favorite

Diffusion Tensor Imaging to Determine Effects of Antidementive Treatment on Cerebral Structural Connectivity in Alzheimer’s Disease

By  

Current Pharmaceutical Design, Vol. 19, Iss. 36, 2013-11 ,pp. : 6416-6425

Bentham Science Publishers

Access to resources Recommend Favorite